[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337269-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337269-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","trim21-promotes-tumor-growth-and-gemcitabine-resistance-in-pancreatic-cancer-by-inhibiting-ephx1-mediated-arachidonic-acid-metabolism","TRIM21 Promotes Tumor Growth and Gemcitabine Resistance in Pancreatic Cancer by Inhibiting EPHX1-Mediated Arachidonic Acid Metabolism","","Pancreatic cancer progresses rapidly, and gemcitabine-based chemotherapy provides limited efficacy. Multi-database analyses identify TRIM21 as a promising driver mediator. Functional loss- and gain-of-function experiments show that TRIM21 knockout suppresses tumor proliferation and gemcitabine resistance in vitro and in vivo. TRIM21 silencing reduces arachidonic acid production and inhibits ferroptosis. Proteomics, ubiquitomics, and LC-MS/MS reveal EPHX1 as a downstream TRIM21 substrate, stabilized to degradation through K33/K48-linked ubiquitination at K105.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/trim21-promotes-tumor-growth-and-gemcitabine-resistance-in-pancreatic-cancer-by-inhibiting-ephx1-mediated-arachidonic-acid-metabolism/337269/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/trim21-promotes-tumor-growth-and-gemcitabine-resistance-in-pancreatic-cancer-by-inhibiting-ephx1-mediated-arachidonic-acid-metabolism/337269.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-15","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is gemcitabine treatment insufficient for pancreatic cancer?","Question",{"text":63,"@type":64},"Clinical response to gemcitabine-based therapy is limited, with overall survival reported in the study’s introduction as roughly 6.7 to 10.1 months and a response rate around 20%.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role does TRIM21 play in pancreatic cancer and gemcitabine resistance?",{"text":68,"@type":64},"TRIM21 is identified as a promising driver mediator; TRIM21 knockout inhibits tumor proliferation and reduces gemcitabine resistance in vitro and in vivo.",{"name":70,"@type":61,"acceptedAnswer":71},"How does TRIM21 influence EPHX1 and arachidonic acid metabolism?",{"text":72,"@type":64},"TRIM21 interacts with EPHX1 via its SPRY domain and promotes ubiquitin-mediated degradation of EPHX1 through K33- and K48-linked ubiquitination at the K105 site, which affects arachidonic acid metabolism.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337269,1790178457,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","RESEARCH ARTICLE  \n[www.advancedscience.com](www.advancedscience.com)  \nTRIM21 Promotes Tumor Growth and Gemcitabine Resistance in Pancreatic Cancer by Inhibiting EPHX1-Mediated Arachidonic Acid Metabolism  \nXiaona Fan, Yisheng Dai, Chuanfeng Mo, Hengzhen Li, Xindi Luan, Bojun Wang, Jiani Yang, Guangtao Jiao, XiaoLin Lu, Zhuo Chen, Yuanyu Liao, Ling Qu, Huike Yang, Changjie Lou,* Chao Liu,* and Zhiwei Li*  \nPancreatic cancer (PC) progresses rapidly, and gemcitabine-based chemotherapy has brought only limited eﬃcacy. Identifying key drivers and therapeutic targets holds signiﬁcant clinical value. In this study, through comprehensive analysis of multiple PC databases, this work identiﬁes TRIM21 as a promising driver mediator. This work further performs loss-and  \ngain-of-function assays for TRIM21, revealing that TRIM21 knockout inhibits tumor proliferation and gemcitabine resistance both in vitro and vivo. Lipidomics reveal that silencing TRIM21 reduce the arachidonic acid production, and inhibit ferroptosis. Mechanically, through proteomics, ubiquitomics, and liquid chromatography-tandem mass  \nspectrometry analysis, the key metabolic enzyme of arachidonic acid-EPHX1 is identiﬁed as a downstream substrate of TRIM21. TRIM21 interacts with EPHX1 through its SPRY domain and promotes ubiquitin-mediated degradation of EPHX1 via K33-and K48-linked ubiquitination at the K105 site. Given the targeting potential, this work screens Bezaﬁbrate to block the interaction between TRIM21 and EPHX1 and validates its sensitizing eﬀect. In summary, TRIM21 promotes tumour growth and gemcitabine resistance in PC by inhibiting EPHX1-mediated arachidonic acid metabolism. This provides a novel and promising target for clinical treatment of PC.  \n1. Introduction  \nPancreatic cancer (PC) is among the most lethal malignancies, with a 5-year survival rate of ≈10% and a mortality-to-incidence ratio of 94% . [1–4] Gemcitabine-based therapies remain the preferred treatment for advanced pancreatic cancer. However, the clinical response rate is only ≈20%, with overall survival ranging from 6.7 to 10.1 months. [5–7] The major driver genes of PC include KRAS (90%), TP53 (71%), CDKN2A (24%), and SMAD4 (17%) . [8,9] Although these are well-established driver genes in PC, their therapeutic potential as clinical drug targets remains limited. [9,10]Therefore, further elucidation of the key events driving the malignant progression and gemcitabine resistance in PC is of great clinical value.  \nTRIM21, a RING-domain E3 ubiquitin ligase, has been demonstrated to exert diverse biological processes such as tumorigenesis, progression, and therapy resistance. [11–14] TRIM21 accelerates  \nliver cancer development by inhibiting p62 ubiquitination, thereby reducing the activity of the Keap1-Nrf2 antioxidant pathway.[11] TRIM21 targets TIF1􀀂 for degradation and promotes  \nX. Fan, Y. Dai, C. Mo, H. Li, X. Luan, B. Wang, J. Yang, G. Jiao, Z. Chen,  \nY. Liao, L. Qu, H. Yang, C. Lou, C. Liu, Z. Li Department of Gastrointestinal Medical Oncology Harbin Medical University Cancer Hospital Harbin 150081, P. R. China  \nE-mail: [9337768@qq.com](9337768@qq.com); [liuchao@hrbmu.edu.cn](liuchao@hrbmu.edu.cn);  \n[lizhiwei@hrbmu.edu.cn](lizhiwei@hrbmu.edu.cn)  \nThe ORCID identiﬁcation number(s) for the author(s) of this article  \ncan be found under [https://doi.org/10.1002/advs.202413674](https://doi.org/10.1002/advs.202413674)[ ](https://doi.org/10.1002/advs.202413674)© 2024 The Author(s). Advanced Science published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \nDOI: 10.1002/advs.202413674  \nX. Fan, Y. Dai, C. Mo, H. Li, X. Luan, B. Wang, J. Yang, G. Jiao, Z. Chen, Y. Liao, C. Liu  \nKey Laboratory of Tumor Immunology in Heilongjiang Harbin Medical University Cancer Hospital  \nHarbin 150081, China X. Lu  \nDepartment of ","cbCaivzN01NdvjC7","https://ap.wps.com/l/cbCaivzN01NdvjC7","pdf",8793878,15,"English","# Introduction\n## Pancreatic cancer burden and limitations of gemcitabine\n## TRIM21 as an E3 ubiquitin ligase in cancer therapy resistance\n# Study Findings (Abstract Summary)","[{\"question\":\"Why is gemcitabine treatment insufficient for pancreatic cancer?\",\"answer\":\"Clinical response to gemcitabine-based therapy is limited, with overall survival reported in the study’s introduction as roughly 6.7 to 10.1 months and a response rate around 20%.\"},{\"question\":\"What role does TRIM21 play in pancreatic cancer and gemcitabine resistance?\",\"answer\":\"TRIM21 is identified as a promising driver mediator; TRIM21 knockout inhibits tumor proliferation and reduces gemcitabine resistance in vitro and in vivo.\"},{\"question\":\"How does TRIM21 influence EPHX1 and arachidonic acid metabolism?\",\"answer\":\"TRIM21 interacts with EPHX1 via its SPRY domain and promotes ubiquitin-mediated degradation of EPHX1 through K33- and K48-linked ubiquitination at the K105 site, which affects arachidonic acid metabolism.\"}]","TRIM21 Promotes Tumor Growth and Gemcitabine Resistance in Pancreatic Cancer by Inhibiting EPHX1-Mediated Arachidonic Acid Metabolism | PDF",1790018432,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/442f377134f5aff4705ab0c436bee515.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d5622a830caad9cc61fd90ac02e4638c.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad47ff4461902edbe1c808f6c8a65018.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8eedc1217b600cbf083f16e96cffd78d.webp",980,1287]